Pieris Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Palvella Therapeutics

11/05/2022 18:09

* Pieris Pharmaceuticals Inc  PIRS.OQ  reported a quarterly
adjusted loss of 7 cents​​ per share for the quarter ended in
March. The mean expectation of two analysts for the quarter was
for a loss of 11 cents per share.
    * Revenue fell 29.7% to $10.99 million from a year ago; 
analysts
expected $11.30 million. 
    * Pieris Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 7 cents​.
    * The mean earnings estimate of analysts had risen by
about 55.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Pieris Pharmaceuticals Inc shares had fallen by 25.7% this
quarter and lost 40.5% so far this year.
    * The company reported a quarterly loss of $5.1 million.
    * Wall Street's median 12-month price target for Pieris
Pharmaceuticals Inc is $8.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated May 11 at 05:09 p.m.  ​All
figures in US dollars unless otherwise stated